قارن الطرق

	مقياس جودة الحياة لحب الشباب (Acne-QoL)	مؤشر نوعية الحياة في طب الأمراض الجلدية للأطفال (cDLQI)	مقياس POEM (مقياس الأكزيما الموجه للمريض)
المجال	الأمراض الجلدية	الأمراض الجلدية	الأمراض الجلدية
العائلة	Process / pipeline	Process / pipeline	Process / pipeline
سنة النشأة	2004	1995	2004
صاحب الطريقة	Halvorsen JA et al.	Lewis-Jones MS, Finlay AY	Charman CR, Venn AJ, Williams HC
النوع	Self-report	Self-report (parent or child proxy)	Self-report
المصدر التأسيسي	Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.
الأسماء البديلة	Acne-Q, Acne-Specific QoL	cDLQI, Pediatric DLQI	POEM Score
ذات صلة	4	3	2
الملخص	Acne-QoL is a disease-specific, patient-administered quality-of-life measure assessing the psychological and social burden of acne vulgaris. Acne is the most common skin disease in adolescents and young adults and causes substantial psychological distress, depression, anxiety, and social impairment disproportionate to its severity. Multiple versions of Acne-QoL exist (19–24 items); all capture emotional, social, and functional impacts. Acne-QoL is essential in clinical trials and observational studies to ensure treatment efficacy encompasses quality-of-life outcomes.	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.